Reprogramming immunosuppressive tumour-associated dendritic cells with GADD45β inhibitors

The ability of dendritic cells to present tumour antigens efficiently to cytotoxic T-cells has led to a continuous focus on exploiting their unique stimulatory abilities in therapeutic cancer vaccinations.[1][1] However, existing clinical strategies utilising dendritic cells have failed to induce